Relaunch

SALOFALK / VIFOR PHARMA
Background
Ulcerative colitis is an inflammatory bowel disease that severely impacts the quality of life. Sadly, it is not curable, but it can be managed with treatment. Salofalk is a drug that reduces inflammation in ulcerative colitis, and has been on the market for a long time.

Assignment
Vifor Pharma has the Nordic distribution rights for the Dr Falk product range. It wanted to relaunch Salofalk with a new communicative style on the Nordic market.

Solution
We created a more modern visual profile, taking care not to detract from the already well-established brand’s recognition. Below are the two units we produced, a film for doctors, and a patient leaflet. All the material was translated and localised into four different languages.

The film clearly illustrated Salofalk’s mechanism of action focusing on the granular form, which can be swallowed. The film was produced in association with Noam Briner.

Salofalk / Vifor Pharma
In the patient leaflet, we decided to use a soft, patient-friendly tone of voice. The leaflet is given to patients starting their treatment with Salofalk, describing the disease and the various dosage forms. The illustrations are by Oliver "Ollanski" Bieräugel.